Skip to main content
EJNMMI Research
Figure 2 | EJNMMI Research

Figure 2

From: 64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

Figure 2

64 Cu-DOTA-trastuzumab PET images of metastatic brain tumors in patients with HER2-positive primary breast tumors. The white arrows show the metastatic brain tumors. Upper panels: 64Cu-DOTA-trastuzumab PET images; lower panels: Gd-DTPA-enhanced T1-weighted MRI images. White arrows indicate metastatic brain lesions detectable by both MRI and 64Cu-DOTA-trastuzumab PET, and a red arrow indicates a lesion detectable by MRI but not by 64Cu-DOTA-trastuzumab PET. In patient no. 2 PET image, non-specific high uptake in blood was noted.

Back to article page